Literature DB >> 23864332

Clinical and radiologic manifestations of pulmonary cryptococcosis in immunocompetent patients and their outcomes after treatment.

Thitiporn Suwatanapongched1, Wasinan Sangsatra, Viboon Boonsarngsuk, Siriorn P Watcharananan, Pimpin Incharoen.   

Abstract

PURPOSE: We aimed to investigate clinical and radiologic manifestations of pulmonary cryptococcosis in immunocompetent patients and their outcomes after treatment.
MATERIALS AND METHODS: We retrospectively reviewed the medical records, initial and follow-up chest computed tomography scans and/or radiographs for initial clinical and radiologic manifestations and outcomes following antifungal treatment of 12 immunocompetent patients diagnosed with pulmonary cryptococcosis between 1990 and 2012.
RESULTS: Twelve patients (age range, 21-62 years; males, eight patients [66.7%]) were included. Nine (75%) patients were symptomatic, eight of whom had disseminated infection with central nervous system involvement. Initial pulmonary abnormalities consisted of single nodules/masses (n=5), single segmental or lobar mass-like consolidation (n=3), multiple cavitary and noncavitary nodules (n=1), and multifocal consolidation plus nodules (n=3). These lesions ranged from less than 1 cm to 15 cm in greatest diameter. Distinct subpleural and lower lung predominance was observed. Seven patients (58.3%) had one or more atypical/aggressive findings, namely endobronchial obstruction (n=4), calcified (n=1) or enlarged (n=4) mediastinal/hilar lymph nodes, vascular compression (n=1), pericardial involvement (n=1), and pleural involvement (n=2). Following antifungal therapy, radiologic resolution was variable within the first six months of eight nonsurgical cases. Substantial (>75%) improvement with some residual abnormalities, bronchiectasis, cavitation, and/or fibrotic changes were frequently observed after 12-24 months of treatment (n=6).
CONCLUSION: Pulmonary cryptococcosis in immunocompetent patients frequently causes disseminated infection with atypical/aggressive radiologic findings that are gradually and/or incompletely resolved after treatment. The presence of nonenhanced low-attenuation areas within subpleural consolidation or mass and the absence of tree-in-bud appearance should raise concern for pulmonary cryptococcosis, particularly in patients presenting with meningitis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23864332     DOI: 10.5152/dir.2013.13049

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  6 in total

1.  Pulmonary cryptococcosis manifesting as diffuse air-space consolidations in an immunocompetent patient.

Authors:  Hye Won Choi; Semin Chong; Mi Kyung Kim; In Won Park
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

2.  Clinical characteristics of disseminated cryptococcosis in previously healthy children in China.

Authors:  Li-Wei Gao; An-Xia Jiao; Xi-Rong Wu; Shun-Ying Zhao; Yun Ma; Gang Liu; Ju Yin; Bao-Ping Xu; Kun-Ling Shen
Journal:  BMC Infect Dis       Date:  2017-05-22       Impact factor: 3.090

3.  Pulmonary Cryptococcosis in the Immunocompetent Patient-Many Questions, Some Answers.

Authors:  John F Fisher; Paula A Valencia-Rey; William B Davis
Journal:  Open Forum Infect Dis       Date:  2016-09-03       Impact factor: 3.835

4.  Clinical analysis in immunocompetent and immunocompromised patients with pulmonary cryptococcosis in western China.

Authors:  Junyan Qu; Xiaoli Zhang; Yang Lu; Xijiao Liu; Xiaoju Lv
Journal:  Sci Rep       Date:  2020-06-10       Impact factor: 4.379

5.  Pulmonary cryptococcosis characteristics in immunocompetent patients-A 20-year clinical retrospective analysis in China.

Authors:  Xiaomeng Hou; Lei Kou; Xiaozhen Han; Rui Zhu; Lan Song; Tao Liu
Journal:  Mycoses       Date:  2019-08-04       Impact factor: 4.377

6.  Cryptococcal pneumonia: the great mimicker.

Authors:  Lasya Thambidurai; R Prabhuradhan; Praveenkumar Singhvi; S Ilanchezhian; Rajoo Ramachandran; Haree Shankar
Journal:  BJR Case Rep       Date:  2017-01-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.